168 related articles for article (PubMed ID: 8284263)
21. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.
Wiggins RC; Bouma BN; Cochrane CG; Griffin JH
Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4636-40. PubMed ID: 270705
[TBL] [Abstract][Full Text] [Related]
22. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation.
Hooley E; McEwan PA; Emsley J
J Thromb Haemost; 2007 Dec; 5(12):2461-6. PubMed ID: 17922805
[TBL] [Abstract][Full Text] [Related]
23. Whale high-molecular-weight and low-molecular-weight kininogens.
Semba U; Shibuya Y; Okabe H; Hayashi I; Yamamoto T
Thromb Res; 2000 Mar; 97(6):481-90. PubMed ID: 10704658
[TBL] [Abstract][Full Text] [Related]
24. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2.
Renné T; Dedio J; Meijers JC; Chung D; Müller-Esterl W
J Biol Chem; 1999 Sep; 274(36):25777-84. PubMed ID: 10464316
[TBL] [Abstract][Full Text] [Related]
25. Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells.
Baird TR; Walsh PN
J Biol Chem; 2003 Jun; 278(23):20618-23. PubMed ID: 12663668
[TBL] [Abstract][Full Text] [Related]
26. Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185 to 224 of the kininogen light chain retains full binding activity.
Tait JF; Fujikawa K
J Biol Chem; 1986 Nov; 261(33):15396-401. PubMed ID: 3096985
[TBL] [Abstract][Full Text] [Related]
27. Association of factor XI and high molecular weight kininogen in human plasma.
Thompson RE; Mandle R; Kaplan AP
J Clin Invest; 1977 Dec; 60(6):1376-80. PubMed ID: 915004
[TBL] [Abstract][Full Text] [Related]
28. Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI.
Li C; Voos KM; Pathak M; Hall G; McCrae KR; Dreveny I; Li R; Emsley J
J Thromb Haemost; 2019 May; 17(5):759-770. PubMed ID: 30801944
[TBL] [Abstract][Full Text] [Related]
29. Fine mapping of the high molecular weight kininogen binding site on blood coagulation factor XI through the use of rationally designed synthetic analogs.
Baglia FA; Jameson BA; Walsh PN
J Biol Chem; 1992 Feb; 267(6):4247-52. PubMed ID: 1740464
[TBL] [Abstract][Full Text] [Related]
30. High molecular weight kininogen-binding site of prekallikrein probed by monoclonal antibodies.
Hock J; Vogel R; Linke RP; Müller-Esterl W
J Biol Chem; 1990 Jul; 265(20):12005-11. PubMed ID: 1694851
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibody to human high-molecular-weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity.
Reddigari SR; Kaplan AP
Blood; 1989 Aug; 74(2):695-702. PubMed ID: 2752143
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of a binding site for platelets in the Apple 3 domain of coagulation factor XI.
Baglia FA; Jameson BA; Walsh PN
J Biol Chem; 1995 Mar; 270(12):6734-40. PubMed ID: 7896818
[TBL] [Abstract][Full Text] [Related]
33. Potentiation of the function of Hageman factor fragments by high molecular weight kininogen.
Liu CY; Scott CF; Bagdasarian A; Pierce JV; Kaplan AP; Colman RW
J Clin Invest; 1977 Jul; 60(1):7-17. PubMed ID: 874091
[TBL] [Abstract][Full Text] [Related]
34. A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets.
Miller TN; Sinha D; Baird TR; Walsh PN
Biochemistry; 2007 Dec; 46(50):14450-60. PubMed ID: 18020374
[TBL] [Abstract][Full Text] [Related]
35. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
Revak SD; Cochrane CG; Griffin JH
J Clin Invest; 1977 Jun; 59(6):1167-75. PubMed ID: 864009
[TBL] [Abstract][Full Text] [Related]
36. A binding site for thrombin in the apple 1 domain of factor XI.
Baglia FA; Walsh PN
J Biol Chem; 1996 Feb; 271(7):3652-8. PubMed ID: 8631976
[TBL] [Abstract][Full Text] [Related]
37. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.
Meier HL; Pierce JV; Colman RW; Kaplan AP
J Clin Invest; 1977 Jul; 60(1):18-31. PubMed ID: 874082
[TBL] [Abstract][Full Text] [Related]
38. Molecular cloning and biochemical characterization of rabbit factor XI.
Sinha D; Marcinkiewicz M; Gailani D; Walsh PN
Biochem J; 2002 Oct; 367(Pt 1):49-56. PubMed ID: 12084014
[TBL] [Abstract][Full Text] [Related]
39. Fourier transform infrared (FT-IR) spectroscopic studies of peptide models for interaction of the binding regions of high molecular weight kininogen and prekallikrein.
Lin Y; Li W; Wu J; Zhang H; Colman RW
Thromb Res; 1998 Apr; 90(2):65-72. PubMed ID: 9684759
[TBL] [Abstract][Full Text] [Related]
40. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.
Lin Y; Harris RB; Yan W; McCrae KR; Zhang H; Colman RW
Blood; 1997 Jul; 90(2):690-7. PubMed ID: 9226169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
